The terminal sialic acids play a key role in modulating immune recognition and cellular interactions, often helping cancer cells evade immune detection and promoting tumor progression when MUC1 is overexpressed or abnormally glycosylated in cancerous tissues [15] This highlights the diagnostic potential of glycosylation changes in PDAC, as many patients present with altered glycan profiles even before the onset of overt disease. Here, MUC1 is linked to neoplasm.